Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
AbbVie is conducting a long-term extension study titled ‘A Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura in Children and Adolescents (Ages 6-17)’. The study aims to assess the safety and tolerability of ubrogepant, a drug approved for adult migraine treatment, in pediatric participants aged 6-17. This research is significant as it addresses the need for effective migraine treatments in children, a group significantly affected by this neurological disorder.
The intervention being tested is ubrogepant, an oral tablet designed to treat migraine attacks. Participants can take up to eight doses per month, with an option for a second dose or rescue medication if needed. This approach seeks to evaluate the drug’s effectiveness and safety in a younger demographic.
The study follows a non-randomized, parallel intervention model without masking, focusing on treatment as its primary purpose. This design allows for direct observation of ubrogepant’s effects on pediatric migraine sufferers.
The study began on January 14, 2022, and is currently enrolling by invitation. The last update was submitted on July 14, 2025. These dates are crucial as they indicate the study’s progress and ongoing nature, providing investors with a timeline for potential outcomes.
This study update could positively impact AbbVie’s stock performance by expanding the market for ubrogepant to include pediatric patients, potentially increasing sales. It also positions AbbVie favorably against competitors in the migraine treatment market, highlighting their commitment to addressing unmet needs in pediatric care.
The study is ongoing, with further details available on the ClinicalTrials portal.